Pasithea Therapeutics Corp. (KTTA) Financials

KTTA Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 51.7 billion 1.9 billion
March 31, 2026 56.4 million 1.5 million
Dec. 31, 2025 60.2 million 5.0 million
Sept. 30, 2025 13.6 million 1.4 million

KTTA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -9.5 billion 469.0 million
March 31, 2026 -4.8 million 139182
Dec. 31, 2025 -5.4 million -67.8 million
Sept. 30, 2025 -2.9 million 52987

KTTA Net Income

No data available :(

KTTA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 45.7 billion - -
March 31, 2026 50.4 million - -
Dec. 31, 2025 55.2 million - -
Sept. 30, 2025 4.1 million - -

KTTA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 32.1 million
March 31, 2026 7.0 million
Dec. 31, 2025 7.0 million
Sept. 30, 2025 7.4 million

KTTA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 3.7 billion 2.0 billion -
March 31, 2026 - 2.9 billion 1.9 billion -
Dec. 31, 2025 2 2.7 million 7.5 million -
Sept. 30, 2025 5 1.4 million 1.8 million -

KTTA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 157541
Dec. 31, 2025 - 157962
Sept. 30, 2025 - 181541

KTTA

Price: $0.50

52 week price:
0.28
2.06

Earnings Per Share: -1.42 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 51500

Market Capitalization: 16.1 million

Links: